A Study of Single Dose Per Cycle Filgrastim-SD/01 as an Adjunct to VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients
Phase 2
N/A
21 Years
N/A
21 Years
Not Enrolling
Both
Sarcoma, Neutropenia
Both
Sarcoma, Neutropenia
Trial Information
A Study of Single Dose Per Cycle Filgrastim-SD/01 as an Adjunct to VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients
Inclusion Criteria
- Sarcoma * No previous chemotherapy or radiotherapy * Patients who will be receiving
chemotherapy consisting of Vincristine, Doxorubicin, Cyclophosphamide, Etoposide,
Ifosfamide, and Mesna
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Outcome Measure:
Duration of severe neutropenia in chemotherapy in cycles 1 and 3
Outcome Time Frame:
cycles 1 and 3
Safety Issue:
No
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Food and Drug Administration
Study ID:
990130
NCT ID:
NCT00035620
Start Date:
April 2000
Completion Date:
April 2007
Related Keywords:
- Sarcoma
- Neutropenia
- Bone cancer
- Sarcoma
- Neutropenia
- Chemotherapy
- Neutropenia
- Sarcoma
Name | Location |
|---|
